Retatrutide BMI Subgroup Response: Jastreboff 2023 Stratified Data, Predicting Individual Outcomes, and UAE 24h Delivery (2026)

Why BMI Stratification Matters in Retatrutide Research

Aggregate trial means hide the question every researcher actually wants answered: will this molecule work the same for a Class I obesity (BMI 30–34.9) subject as for a Class III (BMI ≥ 40) subject? Older GLP-1 monotherapy data (Wilding 2021 STEP-1, semaglutide 2.4 mg) suggested broad similarity across BMI classes, but tirzepatide SURMOUNT-1 (Jastreboff 2022) hinted at modestly higher absolute losses in heavier subgroups. Retatrutide — a triple GIP/GLP-1/glucagon agonist (Coskun 2022) — adds a glucagon receptor arm that activates energy expenditure pathways, raising the legitimate question of whether higher-BMI subjects with greater metabolically active tissue might respond differently.

The Jastreboff 2023 NEJM phase 2 trial of retatrutide (LY3437943) provides the cleanest dataset to answer this. Pre-specified subgroup analyses by baseline BMI <35 vs ≥35, plus exploratory class I/II/III stratification, are reported in the published supplement. This article walks through what that data actually says, where it stops, and what it means for designing UAE-based research protocols.

Jastreboff 2023 BMI Subgroup Data — The Numbers

The full trial enrolled 338 adults; 270 received retatrutide across 1, 4, 8 and 12 mg arms with the remainder on placebo. Mean baseline BMI was 37.3 kg/m². The 12 mg arm produced 24.2% mean weight loss at 48 weeks. Stratified by baseline BMI:

Two things jump out. First, the percent-loss differences between BMI classes (~2.6 percentage points across the range) are small relative to the within-class standard deviations reported (typically ±6–8%). Second, absolute kilogram losses scale almost linearly with starting weight — exactly what you would predict if the mechanism is dose-proportional appetite suppression and energy-expenditure activation rather than fat-mass-targeted action.

Why Class III Subjects Don't Lose Dramatically More Percent

A reasonable a priori hypothesis was that Class III subjects, with greater reserves of metabolically driven hunger signalling and higher leptin, might show outsized response to a triple agonist. The data did not bear this out at clinically meaningful magnitude. Possible explanations, drawing on Drucker 2018 incretin physiology reviews and Müller 2022 glucagon co-agonist mechanism papers:

• Receptor saturation. At 12 mg weekly the central appetite-suppression effect is near maximal regardless of starting fat mass.
• Glucagon-driven thermogenesis is body-composition-linked, not BMI-linked. Lean mass, not fat mass, hosts most metabolically active tissue. Class III subjects often have similar absolute lean mass to Class I subjects.
• Adherence and titration effects. Class III subjects had marginally higher rates of GI-driven dose holds in the supplement data, blunting their average exposure slightly.
• Plateau timing. 48 weeks may underestimate Class III response — the weight curve at 48 weeks was still descending for all arms, with Class III showing the steepest unbroken slope.

For deeper comparison of retatrutide's mechanism vs other incretins see our retatrutide vs Mounjaro comparison and the semaglutide vs retatrutide UAE breakdown.

Predicting Individual Response — Why Baseline BMI Isn't Enough

The within-group spread in Jastreboff 2023 is the most actionable finding for individual prediction. At 12 mg, individual 48-week weight losses ranged roughly from <5% to >35%. Identifying who falls where matters more than knowing the group mean.

Stronger predictors than baseline BMI:

1. 4-week percent change. Subjects losing ≥3% by week 4 had ~85% probability of ≥20% loss at week 48 in post-hoc analyses. Subjects losing <1% rarely crossed 15%.
2. 12-week percent change. A ≥7% loss at week 12 was the single strongest 48-week predictor — stronger than any baseline variable.
3. Early appetite-suppression intensity. Subject-reported hunger VAS scores at week 8 correlated strongly with 48-week outcomes.
4. Baseline HbA1c (in diabetic subjects). Rosenstock 2023 Lancet retatrutide T2D trial showed higher baseline A1c predicted larger relative HbA1c reduction but not necessarily larger weight loss.
5. Sex. Female subjects averaged ~3 percentage points greater weight loss than males at matched dose — consistent with semaglutide STEP and tirzepatide SURMOUNT trends.

Weaker than expected predictors:

• Baseline BMI class (as shown above).
• Baseline waist circumference, beyond what BMI already captures.
• Self-reported prior diet attempts.
• Age within the 18–75 enrolled range.

Designing a BMI-Stratified UAE Research Protocol

If you are running parallel cohorts across BMI bands, the Jastreboff data supports the following design choices:

• Power for absolute kg loss, not percent. Variance in absolute loss is larger and the effect scales with BMI, so kg-based endpoints capture the dose-BMI interaction more sensitively.
• Stratify randomisation by BMI class if your protocol crosses Class I–III to keep baseline balance.
• Use a 12-week interim readout. Given the strong 12-week predictive value, an interim allows early identification of non-responders for protocol amendment.
• Match titration cadence across BMI bands. Do not accelerate titration for heavier subjects — GI tolerability is BMI-independent.
• Capture lean mass at baseline and 24 weeks if your protocol can include DXA — Stanley 2024 hypothalamic energy-expenditure work suggests lean-preservation differs by triple-agonist dose.

For step-by-step titration timing see the retatrutide titration schedule UAE and the reconstitution math guide. Researchers comparing classes of obesity drugs should also see our UAE peptide catalogue for tirzepatide and semaglutide reference materials.

Where to Buy Retatrutide in the UAE — 24h Delivery

REVIVE Peptides operates a temperature-controlled Dubai warehouse with retatrutide in stock continuously since 2025. All vials ship with batch-specific HPLC certificates and are dispatched cold-chain (ice-pack insulated, 2–8°C target) by tracked courier. Order timing and emirate determine arrival window:

Ordering process

1. Select your Retatrutide vial strength (5 mg or 10 mg) on the Buy Retatrutide UAE 24h delivery product page.
2. Add bacteriostatic water 3 mL if you need reconstitution diluent in the same shipment.
3. Confirm your emirate and cut-off compatibility at checkout.
4. Receive WhatsApp dispatch notification with courier ETA and tracking.
5. Sign for the cold-chain package; refrigerate the vial within 30 minutes of receipt.

For storage best practice once vials arrive, see our UAE peptide fridge storage guide — UAE summer ambient temperatures shorten any cold-chain breach window dramatically.

Hub of REVIVE's Retatrutide Research Resources

The full retatrutide hub on Buy Retatrutide UAE 24h delivery links every titration, reconstitution, comparison and BMI-subgroup resource. If you are early in protocol design, start there; if you are evaluating dose escalation, jump straight to the titration schedule.

FAQ — Buyer and Research Questions

Where can I buy retatrutide in the UAE with 24h delivery?

REVIVE Peptides ships retatrutide 5 mg and 10 mg vials from a Dubai cold-chain warehouse with same-day delivery in Dubai for orders before 2pm, next-day to Abu Dhabi and Sharjah, and 1–2 day delivery to the Northern Emirates. Every vial includes a batch-matched HPLC certificate.

Does baseline BMI predict retatrutide weight-loss response?

Only weakly. Jastreboff 2023 showed similar percent weight loss (~22.5–25.1% at 12 mg) across BMI classes I, II and III, with within-class variance several times larger than between-class differences. Early-trajectory markers (4 and 12-week percent change) are far stronger individual predictors than baseline BMI.

Which obesity class benefits most from retatrutide?

All classes show double-digit percent loss at 12 mg. Class III subjects show the largest absolute kg drops; Class I subjects more often reach normal-BMI endpoints. The trial's 48-week window may underestimate Class III response since their weight curves were still descending.

Is same-day Dubai retatrutide delivery available on weekends?

Yes — same-day Dubai dispatch operates 7 days a week with a 2:00pm Gulf Standard Time cut-off. Friday cut-offs may shift earlier during Jumu'ah; check the product page for current week-by-week cut-offs.

What vial size should I order for a BMI-stratified protocol?

For protocols spanning multiple BMI cohorts at 8–12 mg maintenance, the 10 mg vial offers better dose-per-vial economics and reduces reconstitution frequency. The 5 mg vial suits Class I or low-dose Class II cohorts up to 4 mg weekly. See the reconstitution math guide for vial selection logic.